10x Genomics has raised $35 million in an extension of its Series D financing, the company said today.
The round was led by Meritech Capital, with participation from Fidelity and Wells Fargo, and brings the company’s total financing to date to $243 million. Last April, 10x had raised $50 million in the original Series D financing round.
According to 10x, its valuation is $1.28 billion following the financing announced today.
“The 10x team’s deep understanding of biology, chemistry, and math, coupled with its relentless execution, made it a very attractive investment for us,” said Craig Sherman, managing director of Meritech Capital, in a statement. “We are looking forward to partnering with 10x as they scale the company and introduce more innovation into the industry.”
Last year, 10x acquired Spatial Transcriptomics in Sweden and Stanford University spinout Epinomics. It is also moving into a larger facility this year and plans to hire up to 200 new staffers.
“Today’s funding announcement will allow us to continue with this momentum into 2019 as we scale 10x to become a company that impacts billions of lives around the world,” said CEO and Co-founder Serge Saxonov in a statement.